Status:

TERMINATED

Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections

Lead Sponsor:

National Heart, Lung, and Blood Institute (NHLBI)

Conditions:

Chronic Lymphocytic Leukemia

CML (Chronic Myelogenous Leukemia)

Eligibility:

All Genders

18-75 years

Phase:

PHASE1

Brief Summary

Allogeneic hematopoetic stem cell transplantation (SCT) is frequently complicated by life threatening viral reactivation. Conventional antiviral therapy is suboptimal for cytomegalovirus (CMV), adenov...

Detailed Description

Allogeneic hematopoetic stem cell transplantation (SCT) is frequently complicated by life threatening viral reactivation. Conventional antiviral therapy is suboptimal for cytomegalovirus (CMV), adenov...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA: Recipient
  • Ages 18-75 years inclusive
  • Patients with hematologic malignancies who have signed consent for NHLBI transplant protocol 13-H-0144.
  • Susceptible to CMV reactivation post transplant (either donor or recipient need to be seropositive for CMV at any time prior to transplant).
  • Ability to comprehend the investigational nature of the study and provide informed consent.
  • EXCLUSION CRITERIA: Recipient
  • Positive pregnancy test for women of childbearing age.
  • DLCO adjusted for Hb and ventilation \< 50% predicted prior to SCT
  • Left ventricular ejection fraction \< 40% (evaluated by ECHO) or \< 30% (evaluated by MUGA) prior to SCT
  • AST/SGOT \> 10 times ULN (\>grade 3, CTCAE)
  • Bilirubin \> 5 times ULN (\>grade 3, CTCAE)
  • Estimated GFR \< 15 mL/min
  • Receiving Ganciclovir, Foscarnet or Cidofovir
  • Receiving corticosteroids at the dose equivalent to 0.5 mg/kg/day of methylprednisolone
  • Evidence of active autoimmune process

Exclusion

    Key Trial Info

    Start Date :

    September 3 2014

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    December 29 2017

    Estimated Enrollment :

    12 Patients enrolled

    Trial Details

    Trial ID

    NCT02231853

    Start Date

    September 3 2014

    End Date

    December 29 2017

    Last Update

    December 17 2019

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    National Institutes of Health Clinical Center, 9000 Rockville Pike

    Bethesda, Maryland, United States, 20892